A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function

Transplantation

Volumn 71, Issue 9, 2001, Pages 1320-1328

  Hong, Johnny C ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CHIMERIC ANTIBODY; CHOLESTEROL; CYCLOSPORIN A; HEMOGLOBIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; PREDNISONE; RAPAMYCIN;

ADOLESCENT; ADULT; ARTICLE; CADAVER DONOR; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ETHNIC GROUP; FEMALE; GRAFT SURVIVAL; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE; MALE; PRIORITY JOURNAL; RECIPIENT; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035872669     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200105150-00025     Document Type: Article

References (37)

1. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection
2. Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse
3. Nitric oxide synthase activity in ischemia-reperfusion injury in the rat: Implications for renal transplantation
4. Effect of the bioflavonoids quercetin and curcumin on ischemic renal injury: A new class of renoprotective agents
5. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
6. Analysis of the UNOS scientific renal transplant registry at three years-early events affecting transplant success
7. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation: The multivariate analysis
8. The UNOS scientific transplant registry
9. Long-term graft outcome is not necessarily affected by delayed onset of graft function and early acute rejection
10. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
11. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
12. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
13. IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T cell growth factors in allograft rejection
14. Immunopharmacology of rapamycin
15. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression
16. Conversion from liquid to solid sirolimus formulations in stable renal allograft transplant recipients
17. Routine clinical monitoring of sirolimus (rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
18. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
19. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
20. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
21. Challenges in cyclosporine therapy: The role of therapeutic drug monitoring by area under the curve monitoring
22. Pretransplant test-dose pharmacokinetic profiles: Cyclosporine microemulsion versus corn oil-based soft gel capsule formulation
23. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period
24. Prediction of creatinine clearance from serum creatinine
25. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banffworking classification of kidney transplant pathology
26. Time dependency of factors affecting renal allograft survival
27. Immunologic and nonimmunologic factors: Different risks for cadaver and living donor transplantation
28. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function
29. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation
30. Sequential biological immunosuppression: Induction therapy with rabbit antithymocyte globulin
31. Can antibody prophylaxis allow sparing of other immunosuppressives?
32. The effect of rapamycin on kidney function in the Sprague-Dawley rat
33. Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs
34. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
35. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
36. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
37. Cytokine nephropathy during antilymphocyte therapy